By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Miraculins said today that Alere has secured a second exclusive option period on Miraculins' preeclampsia technology and will provide Miraculins a non-refundable fee. Under the terms of the original agreement signed two years ago, Alere is working towards the goal of commercializing Miraculins' preeclampsia technology for worldwide distribution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.